WallStreetZenWallStreetZen

NASDAQ: INKT
Mink Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for INKT

Based on 1 analyst offering 12 month price targets for Mink Therapeutics Inc

Min Forecast
$35.00+201.98%
Avg Forecast
$35.00+201.98%
Max Forecast
$35.00+201.98%

Should I buy or sell INKT stock?

Based on 1 analyst offering ratings for Mink Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their INKT stock forecasts and price targets.

INKT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-18

1 of 1

Forecast return on equity

Is INKT forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is INKT forecast to generate an efficient return on assets?

Company
-153.74%
Industry
23.67%
INKT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INKT earnings per share forecast

What is INKT's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.53
Avg 2 year Forecast
-$2.54
Avg 3 year Forecast
-$3.76

INKT revenue forecast

What is INKT's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$3.5M
Avg 2 year Forecast
$4.1M
Avg 3 year Forecast
$4.2M

INKT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INKT$11.59$35.00+201.98%Buy
XLO$8.98N/AN/A
FRMM$4.46$9.00+101.79%Buy
HRTX$0.32N/AN/AHold
DWTX$1.70$12.00+605.88%Buy
View Top Biotech Stocks

Mink Therapeutics Stock Forecast FAQ

Is Mink Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: INKT) stock is to Buy INKT stock.

Out of 1 analyst, 0 (0%) are recommending INKT as a Strong Buy, 1 (100%) are recommending INKT as a Buy, 0 (0%) are recommending INKT as a Hold, 0 (0%) are recommending INKT as a Sell, and 0 (0%) are recommending INKT as a Strong Sell.

If you're new to stock investing, here's how to buy Mink Therapeutics stock.

What is INKT's earnings growth forecast for 2026-2028?

(NASDAQ: INKT) Mink Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.51%.

Mink Therapeutics's earnings in 2026 is -$11,360,381.On average, 4 Wall Street analysts forecast INKT's earnings for 2026 to be -$12,908,554, with the lowest INKT earnings forecast at -$15,152,854, and the highest INKT earnings forecast at -$10,341,234. On average, 4 Wall Street analysts forecast INKT's earnings for 2027 to be -$12,986,630, with the lowest INKT earnings forecast at -$16,603,127, and the highest INKT earnings forecast at -$8,948,114.

In 2028, INKT is forecast to generate -$19,206,679 in earnings, with the lowest earnings forecast at -$24,954,700 and the highest earnings forecast at -$12,805,984.

What is INKT's revenue growth forecast for 2026-2028?

(NASDAQ: INKT) Mink Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.58%.

Mink Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast INKT's revenue for 2026 to be $17,697,211, with the lowest INKT revenue forecast at $17,003,203, and the highest INKT revenue forecast at $18,217,717. On average, 3 Wall Street analysts forecast INKT's revenue for 2027 to be $20,820,248, with the lowest INKT revenue forecast at $20,003,768, and the highest INKT revenue forecast at $21,432,608.

In 2028, INKT is forecast to generate $21,631,625 in revenue, with the lowest revenue forecast at $18,559,618 and the highest revenue forecast at $24,647,500.

What is INKT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: INKT) forecast ROA is -153.74%, which is lower than the forecast US Biotechnology industry average of 23.67%.

What is INKT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year INKT price target, the average INKT price target is $35.00, with the highest INKT stock price forecast at $35.00 and the lowest INKT stock price forecast at $35.00.

The Wall Street analyst predicted that Mink Therapeutics's share price could reach $35.00 by May 18, 2027. The average Mink Therapeutics stock price prediction forecasts a potential upside of 201.98% from the current INKT share price of $11.59.

What is INKT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: INKT) Mink Therapeutics's current Earnings Per Share (EPS) is -$2.38. On average, analysts forecast that INKT's EPS will be -$2.53 for 2026, with the lowest EPS forecast at -$2.97, and the highest EPS forecast at -$2.03. On average, analysts forecast that INKT's EPS will be -$2.54 for 2027, with the lowest EPS forecast at -$3.25, and the highest EPS forecast at -$1.75. In 2028, INKT's EPS is forecast to hit -$3.76 (min: -$4.89, max: -$2.51).

What is INKT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: INKT) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.